HomeCompareBMY vs OLN

BMY vs OLN: Dividend Comparison 2026

BMY yields 4.17% · OLN yields 2.77%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $96.7K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
OLN
OLN
● Live price
2.77%
Share price
$28.88
Annual div
$0.80
5Y div CAGR
-0.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.8K
Annual income
$327.63
Full OLN calculator →

Portfolio growth — BMY vs OLN

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYOLN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + OLN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
OLN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
OLN
Annual income on $10K today (after 15% tax)
$235.46/yr
After 10yr DRIP, annual income (after tax)
$278.49/yr
At 15% tax rate, BMY beats the other by $33,571.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + OLN for your $10,000?

BMY: 50%OLN: 50%
100% OLN50/50100% BMY
Portfolio after 10yr
$72.2K
Annual income
$20,075.64/yr
Blended yield
27.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
OLN
Analyst Ratings
11
Buy
22
Hold
2
Sell
Consensus: Hold
Price Target
$22.40
-22.4% upside vs current
Range: $18.00 — $26.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
OLN buys
0
No recent congressional trades found for BMY or OLN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYOLN
Forward yield4.17%2.77%
Annual dividend / share$2.49$0.80
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%-0.1%
Portfolio after 10y$120.5K$23.8K
Annual income after 10y$39,823.66$327.63
Total dividends collected$91.0K$3.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$62.73$22.40

Year-by-year: BMY vs OLN ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrOLN PortfolioOLN Income/yrGap
1← crossover$11,271$571.12$10,977$276.73+$294.00BMY
2$12,884$824.20$12,029$283.60+$855.00BMY
3$14,993$1,206.32$13,161$290.16+$1.8KBMY
4$17,839$1,797.27$14,379$296.41+$3.5KBMY
5$21,826$2,738.11$15,687$302.34+$6.1KBMY
6$27,643$4,289.31$17,093$307.98+$10.6KBMY
7$36,534$6,955.64$18,603$313.31+$17.9KBMY
8$50,861$11,770.13$20,224$318.36+$30.6KBMY
9$75,402$20,980.23$21,963$323.13+$53.4KBMY
10$120,504$39,823.66$23,828$327.63+$96.7KBMY

BMY vs OLN: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

OLNStock

Olin Corporation manufactures and distributes chemical products in the United States, Europe, and internationally. It operates through three segments: Chlor Alkali Products and Vinyls; Epoxy; and Winchester. The Chlor Alkali Products and Vinyls segment offers chlorine and caustic soda, ethylene dichloride and vinyl chloride monomers, methyl chloride, methylene chloride, chloroform, carbon tetrachloride, perchloroethylene, hydrochloric acid, hydrogen, bleach products, potassium hydroxide, chlorinated organics intermediates and solvents, and sodium hypochlorite. The Epoxy segment provides epoxy materials and precursors, including aromatics, such as acetone, bisphenol, cumene, and phenol, as well as allyl chloride, epichlorohydrin, and glycerin used for the manufacturers of polymers, resins and other plastic materials, and water purification; liquid and solid epoxy resins that are used in adhesives, marines, protective coatings, composites, and flooring; and converted epoxy resins and additives for use in electrical laminates, paints and coatings, wind blades, electronics, and construction. The Winchester segment offers sporting ammunition products, including shotshells, small caliber centerfire, and rimfire ammunition products for hunters and recreational shooters, and law enforcement agencies; small caliber military ammunition products for use in infantry and mounted weapons; and industrial products comprising gauge loads and powder-actuated tool loads for maintenance applications in power and concrete industries, and powder-actuated tools in construction industry. The company markets its products through its sales force, as well as directly to various industrial customers, mass merchants, retailers, wholesalers, other distributors, and the U.S. Government and its prime contractors. Olin Corporation was incorporated in 1892 and is based in Clayton, Missouri.

Full OLN Calculator →
📬

Get this BMY vs OLN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.